Compare Five9 Inc (FIVN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Novartis AG — how do they compare? Five9 Inc trades at $36.4 (market cap $2.63B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 102.1× Five9 Inc's market cap, and Novartis AG pays a 3.31% dividend while Five9 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Novartis AG for 82 Days on average.
| FIVN | NVS | |
|---|---|---|
Market Cap | $2.63B | $268.57B |
Volume | 1,864,393 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $38.65 | $168.62 |
52-Week Low | $13.61 | $121.80 |
Typical Hold Time | 72 Days | 82 Days |
Enterprise Value | $2.78B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) is trading at $35.15, up 4.06% with strong technical momentum and bullish moving average signals. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability as net income turned positive at $39.42M. Recent quarterly earnings consistently beat expectations, while AI revenue surged 78% YoY to $39M in Q2 2026. The stock trades near resistance at $35 with solid institutional support despite recent insider selling activity.
FIVN presents growth potential driven by AI contact center adoption and subscription revenue expansion, but faces valuation concerns with a 51.69 P/E ratio. Key risks include competitive pressure in CCaaS markets and execution challenges in maintaining current growth trajectory. Analyst consensus remains bullish with 61% buy ratings and $34 price target, though current price exceeds consensus target.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
